Biodesix (BDSX) investor relations material

Business overview and recent performance

• Offers five blood-based Medicare-covered tests for lung cancer, spanning pre- and post-diagnosis care.

• Diagnostic development services contribute just under 10% of annual revenue, partnering with biopharma and diagnostics firms.

• Sales force expanded to over 100 reps, targeting pulmonology and primary care, with plans to reach 120 by year-end.

• Recent clinical trial expanded Nodify CDT test use to smaller nodules, driving adoption and growth.

• Pulmonology volumes grew 31% year-over-year; primary care volumes up 133%, now 15% of total volume.

Financial outlook and profitability

• Reaffirmed full-year revenue guidance of $108M–$114M, targeting ~25% year-over-year growth.

• Focused on achieving positive adjusted EBITDA in the near term, with profitability driven by top-line growth and cost discipline.

• Operational leverage and improved sales rep productivity are key to reaching and maintaining profitability.

• Gross margins remain industry-leading at 82%, with guidance to sustain around 80% long term.

• Laboratory capacity improvements mean no major capital investments needed in the near future.

Commercial strategy and market dynamics

• Sales force expansion is balanced with maintaining operating leverage and profitability.

• Primary care adoption is growing, with easier integration due to existing diagnostic workflows and facilities.

• ASP growth driven by expanded payer coverage and consistent adoption across Nodify CDT, XL2, and VeriStrat.

• Private payer contracting efforts are consistent, focusing on patient access and payment rate uniformity.

• Barriers to entry include strong IP, robust data, and a dedicated pulmonology-focused sales force.